Drug Profile
LY 3084077
Alternative Names: LY3084077Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Fibroblast growth factors; Glucagon-like peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in Singapore (SC, Injection)
- 31 Dec 2013 Eli Lilly completes a phase I trial in healthy volunteers in Singapore (NCT01846702)
- 20 May 2013 Phase-I clinical trials in Diabetes mellitus (healthy volunteers) in Singapore (SC)